Gene therapy represents one of the most significant advancements in the treatment of bleeding disorders. By offering the potential for durable improvements in clotting factor levels with a single infusion, this innovative approach has opened new possibilities for people living with haemophilia and allied conditions. While gene therapy is still evolving, the progress made to…
Haemophilia marks a significant milestone in 2024—three decades since its inception. Since its first issue in October 1994, the esteemed publication has been a vital platform for sharing knowledge on the comprehensive care of haemophilia and fostering collaboration across disciplines. The journal became WFH’s official publication in 1992, and in 2007, became our official journal,…
EU Elections 2024: Call to Action
With the EU Elections 2024 less than a week away, the European Association for Haemophilia and Allied Disorders (EAHAD) calls upon the policy makers to become champions of haemophilia and rare bleeding disorders healthcare like never before. Our mission, dedicated to enhancing clinical care, fostering education, and advancing research,…
EAHAD Statement on upcoming ISTH Guidelines on Haemophilia Treatment
Brussels, 28 May 2024 The European Association for Haemophilia and Allied Disorders (EAHAD) reiterates its commitment to collaborating with all stakeholders to provide the highest quality care within available resources. In October 2023, the International Society on Thrombosis and Haemostasis (ISTH) released draft clinical guidelines on…
EAHAD 2024 Press Release
Brussels, Belgium, 22 February 2024 - The European Association for Haemophilia and Allied Disorders (EAHAD) is delighted to announce the successful conclusion of its 2024 Congress, held from February 6 to 9 in Frankfurt, Germany. Boasting almost 2000 delegates from more than 70 countries and under the direction of Congress President…
